Anti-Enterovirus 68, Capsid (Clone EV-D68-159) - Purified No Carrier Protein (E175-GRP)

EV-D68 is a highly transmissible respiratory disease that primarily impacts children. It is among the 100-plus non-polio enteroviruses and is listed as a NIAID Biodefense Priority Pathogen. The respiratory condition can vary from mild (resembling a common cold) to more severe, potentially resulting in acute flaccid myelitis (AFM), a condition characterized by lasting muscle weakness. The majority of individuals with EV-D68 encounter mild symptoms and recuperate without significant complications1. No vaccines are currently accessible for preventing EV-D68 infections, but practical measures can aid in lowering the chances of transmission. The virus is transmitted via respiratory secretions (saliva, nasal mucus, and sputum) when an infected individual coughs, sneezes or makes contact with surfaces subsequently touched by others2. Clone EV-D68-159 light chain CDR1 and CDR3 bind to three residues on the C terminus of VP1(Glu271, Arg272, and Asp285); however, the heavy chain CDR2 and and CDR3 bind the N-terminal loop of VP3 before the B-β strand. The capsid is made up of four viral proteins (VP1, VP2, VP3, and VP4) that are crucial for the virus's ability to bind and enter host cells. Clone EV-D68-159 effectively binds and neutralizes clade B virus, preventing it from infecting cells and spreading4.